Proposal for SP600125 (Sigma-Aldrich catalog #S5567)

Overview of Therapeutic Candidate:
SP600125 is a synthetic small‐molecule inhibitor that was discovered through high‐throughput biochemical screening intended to identify compounds that inhibit c-Jun N-terminal kinase (JNK) activity by targeting its ATP‐binding site. It belongs to the anthrapyrazolone class of compounds, a subclass of synthetic small molecules characterized by their planar structure and nitrogen-containing moieties that enable ATP-competitive inhibition of kinases. This compound was initially synthesized by modifications of anthraquinone structures to yield a molecule with specific inhibitory activity against JNK isoforms (Bennett et al., 2001). The anthrapyrazolone class has, over time, been widely used as research tools to dissect JNK-dependent signaling pathways in various cell types. In preclinical contexts these compounds have demonstrated the ability to inhibit stress-induced signaling cascades, modulating inflammatory responses and apoptosis, which are mechanisms relevant both in metabolic dysfunction and in ovarian pathophysiology (Bennett et al., 2001; Wu et al., 2018).

Therapeutic History:
Historically, SP600125 has been used extensively as a pharmacological tool in cell culture and animal models to elucidate the roles of JNK in inflammation, apoptosis, and cell cycle regulation. Preclinical applications have included studies in models of rheumatoid arthritis, inflammatory lung disease, and even in cancer models as a mechanism to modulate abnormal cellular proliferation (Bennett et al., 2001; Bildik et al., 2018). Despite its widespread use in preclinical research, no clinical trials registered on ClinicalTrials.gov have directly evaluated SP600125 or related JNK inhibitors for Polycystic Ovary Syndrome (ClinicalTrials.gov, n.d.). In the ovarian context, SP600125 has been employed in preclinical studies to assess the role of JNK signaling in granulosa cell function and ovarian inflammation, for example in studies investigating lysyl oxidase regulation in PCOS models where IL-1β induced LOX expression is partially blocked by SP600125 in granulosa cells (Zhang et al., 2018). However, evidence of its use in directly targeting theca cells or modulating insulin resistance mechanisms in PCOS is limited to preclinical reports demonstrating that JNK inhibition can improve ovarian morphology and hormone regulation when combined with insulin sensitizers like metformin and pioglitazone (Wu et al., 2018).

Mechanism of Action:
SP600125 acts as a reversible, ATP-competitive inhibitor of JNK isoforms (JNK1, JNK2, and JNK3). At the molecular level, it binds to the conserved ATP-binding pocket of JNK, thereby preventing phosphorylation of downstream targets such as c-Jun, a component of the activator protein-1 (AP-1) transcription factor complex (Bennett et al., 2001). This inhibition leads to a decreased transcription of genes that are normally induced by JNK activation, including pro-inflammatory cytokines and certain mediators of cell proliferation and apoptosis. Notably, JNK is known to phosphorylate insulin receptor substrate-1 (IRS-1) on serine residues, which, when hyperphosphorylated, impairs insulin receptor signaling by reducing the subsequent tyrosine phosphorylation events essential for PI3K/Akt pathway activation (Lewis et al., 2003; Tuncman et al., 2006). Thus, SP600125 by inhibiting JNK activity is expected to reduce IRS-1 serine phosphorylation, restore its tyrosine phosphorylation, and subsequently improve downstream insulin signaling. In various cell types such as adipocytes and hepatocytes, such an approach has shown promise in restoring insulin sensitivity, and this pharmacological action provides the rationale for targeting ovarian theca cells in PCOS where JNK-driven insulin resistance is implicated (Solinas & Becattini, 2017; Wu et al., 2018).

Expected Effect:
The hypothesis underlying the proposed use of SP600125 in PCOS is that JNK-mediated serine phosphorylation of IRS-1 underlies insulin resistance in ovarian theca cells, a critical component in the altered steroidogenesis and hyperinsulinemia observed in PCOS. By administering SP600125, one expects to inhibit JNK activity in theca cells, thereby preventing aberrant IRS-1 serine phosphorylation. This mechanistic intervention should restore the normal tyrosine phosphorylation events on IRS-1, facilitating proper activation of the PI3K/Akt signaling cascade. Enhanced PI3K/Akt activity would lead to improved insulin-stimulated glucose uptake and metabolic function within the ovary, potentially ameliorating both insulin resistance and the associated hyperandrogenism characteristic of PCOS (Wu et al., 2018; Lewis et al., 2003). Furthermore, studies in rodent PCOS models have demonstrated that combining the JNK inhibitor with metformin and pioglitazone enhances ovarian follicular development and reduces pathological ovarian features, supporting the potential benefit of supplementing standard insulin-sensitizing therapies with direct JNK inhibition (Wu et al., 2018; Zhang et al., 2018). Although direct data in theca cells are sparse, related work in granulosa cells suggests that SP600125 has a measurable impact on key ovarian signaling pathways involved in inflammation and extracellular matrix remodeling—pathways that are also tied to insulin signaling (Zhang et al., 2018).

Overall Evaluation:
SP600125 appears to offer a promising mechanism-based approach for the treatment of PCOS by directly targeting JNK, a critical kinase implicated in the disruption of insulin signaling via IRS-1 serine phosphorylation. Among its strengths are its well-characterized biochemical action, its reversible ATP-competitive inhibition of JNK, and its demonstrated ability to modulate inflammatory and stress-related signaling pathways in various cell types and animal models (Bennett et al., 2001; Wu et al., 2018). The literature supports that JNK inhibition can restore insulin signaling in metabolic tissues, and preclinical data in ovarian models suggest that similar benefits may extend to the impaired insulin responsiveness observed in PCOS (Lewis et al., 2003; Solinas & Becattini, 2017). Furthermore, SP600125’s use in research involving ovarian granulosa cells bolsters the rationale for its application in modulating ovarian function, potentially addressing both insulin resistance and hyperandrogenism through improved PI3K/Akt signaling (Zhang et al., 2018; Wu et al., 2018).

However, several weaknesses and uncertainties temper the enthusiasm for repurposing SP600125 as a therapeutic for PCOS. First, there is a notable lack of direct clinical or preclinical evidence specifically in the ovarian theca cell context, as most studies have focused on granulosa cells or more systemic metabolic models. While the mechanistic rationale is sound, validation in PCOS-specific models, particularly those examining the impact on IRS-1 phosphorylation in theca cells and subsequent regulation of the PI3K/Akt pathway, remains limited (Wu et al., 2018; Zhang et al., 2018). Second, potential off-target effects have been observed with SP600125 at higher concentrations; transcriptomic analyses indicate that SP600125 can modulate a broad range of genes beyond its intended target, raising concerns about cellular toxicity and non-specific effects (El Atifi & Champelovier, 2010). Moreover, while rodent studies suggest a tolerable safety profile, systemic effects such as those demonstrated in hepatic ischemia/reperfusion models caution that careful dose optimization and safety profiling will be necessary (Lee et al., 2006). Finally, the absence of any registered clinical trials for SP600125 in PCOS or related insulin resistance conditions indicates that significant translational and regulatory hurdles remain before it can be considered a viable therapeutic candidate (ClinicalTrials.gov, n.d.).

In summary, SP600125 provides a compelling pharmacological tool based on an attractive hypothesis: by inhibiting JNK in ovarian theca cells, it may alleviate insulin resistance through the restoration of proper IRS-1 signaling and consequent activation of the PI3K/Akt pathway, which in turn could improve ovarian function in PCOS. Its strengths lie in its defined mechanism of action and demonstrated preclinical activity in related pathways, while its weaknesses relate to the need for further validation in PCOS-specific models, concerns regarding off-target and safety profiles, and the current lack of clinical data. Overall, while SP600125 holds promise for repurposing in PCOS treatment, further targeted studies—both in vitro (particularly in theca cells) and in relevant in vivo PCOS models—are essential to establish its therapeutic efficacy and safety before advancing to clinical trials (Wu et al., 2018; Bennett et al., 2001; Lewis et al., 2003).

References
Bennett, B. L., Sasaki, D. T., Murray, B. W., O’Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., Bhagwat, S. S., Manning, A. M., & Anderson, D. W. (2001). SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proceedings of the National Academy of Sciences, 98, 13681–13686. https://doi.org/10.1073/pnas.251194298

Bildik, G., Akin, N., Senbabaoglu, F., Esmalian, Y., Sahin, G. N., Urman, D., Karahuseyinoglu, S., Ince, U., Palaoglu, E., Taskiran, C., Arvas, M., Guzel, Y., Yakin, K., & Oktem, O. (2018). Endogenous c-Jun N-terminal kinase (JNK) activity marks the boundary between normal and malignant granulosa cells. Cell Death & Disease. https://doi.org/10.1038/s41419-018-0459-3

ClinicalTrials.gov. (n.d.). ClinicalTrials.gov search results for SP600125 or JNK inhibitor and Polycystic Ovary Syndrome [Search results]. Retrieved from https://clinicaltrials.gov/ct2/results?cond=SP600125+OR+JNK+inhibitor+AND+%28Polycystic+Ovary+Syndrome+OR+PCOS+OR+ovarian+insulin+resistance%29

El Atifi, M., & Champelovier, P. (2010). Inhibition of c-Jun N-terminal kinase by SP600125: A cDNA microarray analysis. Unknown Journal.

Lee, K.-H., Kim, S.-E., & Lee, Y.-S. (2006). SP600125, a selective JNK inhibitor, aggravates hepatic ischemia–reperfusion injury. Experimental & Molecular Medicine, 38, 408–416. https://doi.org/10.1038/emm.2006.48

Lewis, A. J., Bennett, B. L., & Satoh, Y. (2003). JNK: A new therapeutic target for diabetes. Current Opinion in Pharmacology, 3, 420–425. https://doi.org/10.1016/S1471-4892(03)00068-7

Solinas, G., & Becattini, B. (2017). JNK at the crossroad of obesity, insulin resistance, and cell stress response. Molecular Metabolism, 6, 174–184. https://doi.org/10.1016/j.molmet.2016.12.001

Tuncman, G., Hirosumi, J., Solinas, G., Chang, L., Karin, M., & Hotamisligil, G. S. (2006). Functional in vivo interactions between JNK1 and JNK2 isoforms in obesity and insulin resistance. Proceedings of the National Academy of Sciences, 103, 10741–10746. https://doi.org/10.1073/pnas.0603509103

Wu, Y., Li, P., Zhang, D., & Sun, Y. (2018). Metformin and pioglitazone combination therapy ameliorate polycystic ovary syndrome through AMPK/PI3K/JNK pathway. Experimental and Therapeutic Medicine. https://doi.org/10.3892/etm.2017.5650

Zhang, C., Ma, J., Wang, W., Sun, Y., & Sun, K. (2018). Lysyl oxidase blockade ameliorates anovulation in polycystic ovary syndrome. Human Reproduction, 33, 2096–2106. https://doi.org/10.1093/humrep/dey292
